M&A isn’t just for big pharma. Mid-size companies are stepping up deal hunts
In what is shaping up to be one of the most active years for biopharma M&A on record, a different-looking set of buyers is going shopping. Mid-cap American drugmakers, family-owned pharma groups, foundation-governed European players ...
May 15, 2026 08:43 AM EDT FinancingDeals M&A isn’t just for big pharma. A diverse group of mid-size companies are stepping up dealmaking Kyle LaHucik Biotech Correspondent In what is shaping up to be one of the most active years for biopharma M&A on record, a different-looking set of buyers is going … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that